John P Leonard Selected Research

Non-Hodgkin Lymphoma (Lymphosarcoma)

1/2022	Worsening Quality of Life in Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients in Active Surveillance: A 12-Month Longitudinal Study.
11/2021	Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study.
1/2019	Autologous transplantation as consolidation for high risk aggressive T-cell non-Hodgkin lymphoma: a SWOG 9704 intergroup trial subgroup analysis.
1/2018	Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis.
1/2017	Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
12/2016	Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma.
12/2015	Idelalisib-associated Colitis: Histologic Findings in 14 Patients.
11/2015	Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance).
2/2015	Phase 1 study of radiosensitization using bortezomib in patients with relapsed non-Hodgkin lymphoma receiving radioimmunotherapy with 131I-tositumomab.
1/2015	Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

John P Leonard Research Topics

Disease

55	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022 - 02/2002
52	Lymphoma (Lymphomas) 07/2022 - 02/2002
49	Neoplasms (Cancer) 01/2022 - 02/2002
29	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 12/2021 - 09/2005
27	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2022 - 07/2005
23	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2022 - 08/2004
12	Hodgkin Disease (Hodgkin's Disease) 10/2020 - 08/2002
10	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 09/2003
10	B-Cell Lymphoma (Lymphoma, B Cell) 11/2021 - 08/2005
7	Neutropenia 06/2020 - 05/2014
7	Multiple Myeloma 01/2018 - 10/2006
5	Disease Progression 01/2022 - 12/2008
4	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 02/2007 - 11/2002
3	Diarrhea 10/2019 - 12/2015
3	Infections 10/2019 - 12/2006
3	Anemia 10/2019 - 07/2005
3	Exanthema (Rash) 04/2017 - 11/2016
2	Fatigue 06/2020 - 11/2015
2	Colitis 12/2016 - 12/2015
2	Leukemia 10/2016 - 11/2015
2	Genetic Translocation (Chromosomal Translocation) 01/2016 - 03/2010
2	Fabry Disease (Fabry's Disease) 04/2015 - 03/2015
2	Thrombocytopenia (Thrombopenia) 05/2014 - 12/2010
2	Polycystic Kidney Diseases (Polycystic Kidney Disease) 08/2012 - 07/2010
2	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 11/2010 - 07/2009
2	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 10/2009 - 04/2004
2	Hematologic Neoplasms (Hematological Malignancy) 02/2008 - 08/2006
2	Cytopenia 02/2008 - 07/2005
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 08/2007 - 06/2005
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 08/2007 - 06/2005
2	Burkitt Lymphoma (Burkitt's Lymphoma) 10/2006 - 09/2003
1	Heart Failure 01/2022

Drug/Important Bio-Agent (IBA)

46	Rituximab (Mabthera)FDA Link 11/2021 - 02/2002
23	Monoclonal AntibodiesIBA 01/2021 - 02/2002
16	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2021 - 05/2008
15	Prednisone (Sone)FDA LinkGeneric 11/2021 - 05/2008
14	Lenalidomide (CC 5013)FDA Link 01/2021 - 09/2007
13	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 07/2008
13	Vincristine (Oncovin)FDA LinkGeneric 11/2021 - 07/2008
12	Biological ProductsIBA 01/2021 - 07/2005
11	Bortezomib (Velcade)FDA Link 01/2020 - 09/2006
10	epratuzumabIBA 11/2013 - 02/2002
8	Bendamustine Hydrochloride FDA Link 01/2021 - 01/2010
7	Etoposide (VP 16)FDA LinkGeneric 11/2021 - 05/2008
7	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2015
7	Proteins (Proteins, Gene)FDA Link 01/2019 - 09/2003
7	IodineIBA 01/2018 - 12/2004
6	idelalisibIBA 06/2018 - 06/2013
5	Pharmaceutical PreparationsIBA 11/2020 - 02/2002
5	palbociclibIBA 12/2019 - 05/2012
5	ibrutinibIBA 01/2019 - 09/2014
5	tositumomab I-131 (Bexxar)FDA Link 04/2016 - 10/2005
4	Cyclin D1IBA 12/2019 - 03/2010
4	Dexamethasone (Maxidex)FDA LinkGeneric 08/2012 - 09/2007
4	AntigensIBA 04/2003 - 02/2002
3	ofatumumab FDA Link 10/2019 - 01/2017
3	ceramide glucosyltransferaseIBA 01/2019 - 04/2015
3	Transaminases (Aminotransferases)IBA 12/2016 - 12/2010
3	GlycolipidsIBA 01/2016 - 03/2015
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2014 - 10/2006
3	ORALIT (ORS)IBA 04/2012 - 08/2004
3	Procarbazine (Matulane)FDA Link 04/2012 - 05/2008
3	Immunoconjugates (Immunoconjugate)IBA 01/2012 - 02/2002
3	Iodine-131IBA 06/2010 - 04/2003
3	AntibodiesIBA 03/2006 - 04/2003
2	navitoclaxIBA 01/2021 - 12/2010
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 09/2013
2	Proteasome InhibitorsIBA 12/2019 - 02/2011
2	Interleukin-10 (Interleukin 10)IBA 01/2019 - 09/2003
2	EnzymesIBA 01/2019 - 04/2015
2	CytokinesIBA 01/2019 - 06/2009
2	ChemokinesIBA 01/2019 - 09/2002
2	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 10/2016 - 02/2004
2	Protein Isoforms (Isoforms)IBA 12/2015 - 11/2015
2	GalactosidasesIBA 04/2015 - 03/2015
2	milatuzumabIBA 01/2015 - 01/2009
2	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 04/2014 - 10/2006
2	Indicators and Reagents (Reagents)IBA 03/2011 - 12/2006
2	Inosine Triphosphate (ITP)IBA 10/2009 - 04/2004
2	Clarithromycin (Biaxin)FDA LinkGeneric 07/2008 - 02/2008
2	Immunoglobulin G (IgG)IBA 06/2007 - 09/2003
2	fludarabineIBA 08/2006 - 08/2005
2	apolizumabIBA 02/2002 - 02/2002
2	Humanized Monoclonal AntibodiesIBA 02/2002 - 02/2002
1	cc-486IBA 01/2022
1	oxidized low density lipoproteinIBA 01/2022

Therapy/Procedure

66	Therapeutics 07/2022 - 02/2002
24	Drug Therapy (Chemotherapy) 01/2021 - 08/2002
9	Immunotherapy 01/2019 - 02/2002
7	Radioimmunotherapy 01/2018 - 04/2003
4	Stem Cell Transplantation 01/2021 - 08/2006
4	Aftercare (After-Treatment) 10/2019 - 07/2005
4	Combination Drug Therapy (Combination Chemotherapy) 10/2016 - 05/2008
3	Radiotherapy 10/2020 - 12/2006
2	Cell Transplantation 12/2021 - 01/2021
2	Transplantation 01/2021 - 08/2006
2	Salvage Therapy 01/2021 - 04/2010
2	Homologous Transplantation 01/2021 - 08/2006
2	Biological Therapy 01/2021 - 11/2015
2	Splenectomy 02/2012 - 04/2008